Life Sciences Report
Think Like A Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives On 6 Exciting Biotechs
May. 16, 2014
Approval can come much earlier than July 15. I doubt the FDA needs the entire 90 days to come to a decision to approve the product and figure out the final labeling. The FDA does not have unlimited mapower, and it probably wants to move on to other NDAs. I believe the FDA knows where it's going with Afrezza and would like to get this wrapped up quickly
Renowned Dr. Says will make needles obsolete Read article
Life Sciences Report
Article :Think Like A Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives On 6 Exciting Biotechs
example : india
Great company. Sales Booming.
Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa
BY Adam Feuerstein | 04/02/14 - 06:07 AM EDT
NEW YORK (TheStreet) -- Mannkind (MNKD_) By a 13-1 margin, experts on the panel voted to recommend the approval of Afrezza as a new insulin therapy for Type 1 diabetics. The same panel supported Afrezza use in Type 2 diabetics by a 14-0 vote.
Congratulations to Mannkind and its supporters, who were clearly right to believe in Afrezza's approval chances. The panel votes were overwhelmingly positive and should compel the FDA to approve the new in
haled insulin. Mannkind skeptics who believed FDA criticism of Afrezza would persuade the panel to reject the new insulin were wrong. I was one of those Afrezza non-believers, predicting a negative panel vote for both Type 1 and Type 2 diabetes. I was wrong.
covered and long, yes I admit it.
earnings will be over 200% and forward guidance will be off the charts with their new family EV . Have to run to a meeting don't have time to post about guidance on stocktwits, can someone post.
they have the best charts.
Alternative Energy China Requires 30% of State Cars to be Electric Cars.
By Bloomberg News
Intercept Pharmaceuticals PT Raised to $500.00 at RBC Capital (ICPT)
August 12th, 2014 • 0 comments • Filed Under • by ABMN Staff
Share on StockTwits
Intercept Pharmaceuticals Inc logoStock analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $425.00 to $500.00 in a report issued on Tuesday. The firm curently has an “outperform” rating on the stock.
New York Times
The Street Insider
Facebook (FB): Add Positions Ahead of Q3 Print, Says Deutsche Bank
October 16, 2014Deutsche Bank maintained a Buy rating on Facebook (NASDAQ: FB) with a price target of $90. Analyst Ross Sandler recommends.
Mac Daily News
Morgan Stanley : Apple on pace to sell record 39 million iPhones this quarter
Tuesday, June 10, 2014 ·
Tesla Rises After Musk Tweets About Record Global Sales
By Madeline O’Leary
sold another biotech for MNKD.